Business Wire

Think You Know How to Spot a Scam? New Visa Report Finds That Even Savvy Consumers Get Tripped Up by the Language of Fraud

16.11.2022 16:00:00 EET | Business Wire | Press release

Share

It's not your imagination. Digital scams are everywhere in our daily lives. And as the holiday season approaches, fraudsters are counting on you to let your guard down and take the bait. Whether in the workplace or on the go, we're peppered by phone, text and email with offers for "free gifts" and traps to "act now" to supply personal information before a vital service gets cut off. And this barrage of “fraudulese” is working.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116005258/en/

A new research report out today from Visa (NYSE: V), in partnership with Wakefield Research, “Fraudulese: The Language of Fraud,” brings to light that when it comes to spotting scams, cybercriminals are finding vulnerabilities among even the most tech-savvy consumers. While nearly half of the population are confident they can recognize a scam, 73% are likely to miss the requisite red flags in digital communications.

From a spoofed service notification from your electric company, to an email alerting you that you’ve won products from your favorite store, or even job postings that make it seem like you’ve been hired by a top-tier company, scams hit almost every touchpoint in our digital lives. In the last year alone, Visa has proactively blocked $7.2 billion in attempted fraudulent payments across 122 million transactions before those transactions impacted clients.

“Understanding the language of fraud is increasingly essential in our digital-first world. Scammers have reached new heights of sophistication in both language and variety – no one is immune,” said Paul Fabara, Chief Risk Officer, Visa. “Education around the language of scams is an integral part of our consumer protection, and highlighting the commonalities in the language of fraud helps prevent crime globally.”

Earlier this year as part of Visa’s efforts to empower consumers to learn about the language of fraud, the company commissioned a first-of-its-kind linguistic analysis by researchers in the U.K. revealing how language can be used by fraudsters in short messages. The study revealed that solutions inviting consumers to engage with a problem or offer are the most common fraudulent message, occurring in 87% of the scam text messages, while problem statements that provoke action from the recipient were the second most common.

“By highlighting the communicative strategies, words and phrases used by fraudsters, we hope people can more easily spot the language of fraud as it stands today, which ultimately helps to protect them,” said Dr. Marton Petyko, from the Aston Institute for Forensic Linguistics, which conducted the U.K. research.

Exploring The Language of Fraud: A Disconnect Between Awareness and Action

Falling victim to cyber fraud is costly. In 2021, the FBI’s Internet Crime Complaint Center reported a record number of complaints, with potential losses exceeding $6.9 billion, up from $4.1 billion in 2020.

According to Visa’s new report, which surveyed 6,000 adults in 18 markets worldwide, scammers appear to be thriving in the gap between consumers’ awareness of the language of fraud and their actual behavior. Among the top findings:

  • We think others are more susceptible to fraud than we are. While consumers feel confident in their own vigilance, the vast majority (90%) are concerned that friends or family members may fall for potential scams that include emails or text messages asking people to verify their account information, asking about overdrawn banking accounts and notifying them about winning a gift card or product from an online shopping site.

    The most enticing clickbait messages capitalize on consumer excitement, and fraudulently tout “winning,” “exclusive deals” or “free gift,” the survey found.
  • Is it legitimate? More than 4 in 5 (81%) respondents check the wrong details to determine the authenticity of a communication, focusing on features scammers can easily fake, including the company’s name or logo (46%). Individuals can better protect themselves from fraudsters by checking details that are harder to fake, such as account numbers or details about their interactions with the company.
  • Overlooking telltale signs. Only 60% of people reported looking to ensure a communication is sent from a valid email address. Fewer than half (47%) look to ensure words are spelled properly.
  • Crypto users proceed with caution. Crypto users are more likely to identify the right kind of verifying elements of a potential scam than non-crypto owners. For example, they are more likely to check their account information (49% vs 37%) to confirm the validity of digital communications.

Take a Few Extra Moments to Decipher Fraudulese

Consumers can better protect themselves by taking a few extra moments before clicking, including taking time to understand the way fraudsters use language. Among simple, but effective best practices: Keep personal information to yourself. Don’t click on links before verifying they’ll take you where they say they will. Turn on purchase alerts, which provide near real-time notification by text message or email of purchases made with your account. Call the number on corporate websites or the back of your credit and debit cards if you are unsure if a communication is valid – don't just call the number possibly provided by the scammer in their text or email.

Protection Is Visa’s Top Priority

While cybercrime persists in an increasingly digital world, Visa is mission-driven to protect consumers and mitigate fraud. Over the past five years, the company has invested more than $10 billion in technology, including to reduce fraud and increase network security. More than a thousand dedicated specialists protect Visa’s network from malware, zero-day attacks and insider threats 24x7x365. In fact, over the last 12 months, Visa’s real-time monitoring has proactively blocked over $7.2 billion in fraudulent payments, preventing many from ever knowing they were at risk of a potential fraudulent transaction. Learn more at visa.com/security.

About Visa

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa, visa.com/blog and @VisaNews.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Meg Omecene
347-519-9812
momecene@visa.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye